Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | CD69 | Q07108 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.50 |
| ▸ | AMY2A | P04746 | 2/20 | 0.45 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449498 | 0.95 | LGALS3 (0.54) | LGALS3LGALS8LGALS4CD69MAPK1 | |
| SCHEMBL20390677 | 0.94 | LGALS3 (0.55) | LGALS3LGALS8LGALS4CD69MAPK1 | |
| SCHEMBL29511801 | 0.93 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69MAPK1 | |
| SCHEMBL30527825 | 0.93 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69MAPK1 | |
| SCHEMBL16298821 | 0.93 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69MAPK1 | |
| SCHEMBL29540924 | 0.92 | LGALS3 (0.58) | LGALS3LGALS8LGALS4CD69MAPK1 | |
| SCHEMBL29737502 | 0.92 | LGALS3 (0.58) | LGALS3LGALS8LGALS4CD69MAPK1 | |
| SCHEMBL17148015 | 0.92 | LGALS3 (0.60) | LGALS3LGALS8LGALS4CD69MAPK1 | |
| SCHEMBL29419069 | 0.92 | LGALS3 (0.60) | LGALS3LGALS8LGALS4CD69MAPK1 | |
| SCHEMBL30110520 | 0.92 | LGALS3 (0.60) | LGALS3LGALS8LGALS4CD69MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11291209-B2 | Compositions and methods for making and using hydrolytic enzymes for degrading polysaccharides made by foodborne pathogenic bacteria | UNIVERSITY OF WYOMING (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291209-B2 | Compositions and methods for making and using hydrolytic enzymes for degrading polysaccharides made by foodborne pathogenic bacteria | MGAM, PGLS, LCT | LGALS3 439/4885LGALS8 704/4885LGALS4 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.